Excited-state electronic properties, structural studies, noncovalent interactions, and inhibition of the novel severe acute respiratory syndrome coronavirus 2 proteins in Ripretinib by first-principle simulations
- PMID: 33390634
- PMCID: PMC7765765
- DOI: 10.1016/j.molliq.2020.115134
Excited-state electronic properties, structural studies, noncovalent interactions, and inhibition of the novel severe acute respiratory syndrome coronavirus 2 proteins in Ripretinib by first-principle simulations
Abstract
Ripretinib is a recently developed drug for the treatment of adults with advanced gastrointestinal stromal tumors. This paper reports an attempt to study this molecule by electronic modeling and molecular mechanics to determine its composition and other specific chemical features via the density-functional theory (DFT), thereby affording sufficient information on the electronic properties and descriptors that can enable the estimation of its molecular bioactivity. We explored most of the physico-chemical properties of the molecule, as well as its stabilization, via the studies of the natural bond orbitals and noncovalent interactions. The electronic excitation, which is a time-dependent process, was examined by the time-dependent DFT with a CAM-B3LYP functional. The molecular docking study indicated that Ripretinib strongly docks with three known novel severe acute respiratory syndrome coronavirus 2 (SARS-n-CoV-2) proteins with a reasonably good docking score.
Keywords: Density-functional theory; Molecular docking; Ripretinib; Severe acute respiratory novel coronavirus 2; Time-dependent density-functional theory.
© 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Authors declare no conflicts of interest.
Figures







Similar articles
-
Structural and physico-chemical evaluation of melatonin and its solution-state excited properties, with emphasis on its binding with novel coronavirus proteins.J Mol Liq. 2020 Nov 15;318:114082. doi: 10.1016/j.molliq.2020.114082. Epub 2020 Aug 23. J Mol Liq. 2020. PMID: 32863490 Free PMC article.
-
[Homologous modeling and binding ability analysis of Spike protein after point mutation of severe acute respiratory syndrome coronavirus 2 to receptor proteins and potential antiviral drugs].Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Dec 21;53(1):150-158. doi: 10.19723/j.issn.1671-167X.2021.01.023. Beijing Da Xue Xue Bao Yi Xue Ban. 2020. PMID: 33550350 Free PMC article. Chinese.
-
Detailed molecular structure (XRD), conformational search, spectroscopic characterization (IR, Raman, UV, fluorescence), quantum mechanical properties and bioactivity prediction of a pyrrole analogue.Heliyon. 2020 Jun 3;6(6):e04106. doi: 10.1016/j.heliyon.2020.e04106. eCollection 2020 Jun. Heliyon. 2020. PMID: 32529077 Free PMC article.
-
Thyroid complications of SARS and coronavirus disease 2019 (COVID-19).Endocr J. 2021 Feb 28;68(2):129-136. doi: 10.1507/endocrj.EJ20-0443. Epub 2021 Jan 19. Endocr J. 2021. PMID: 33473054 Review.
-
Ripretinib.2023 Oct 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Oct 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 37956235 Free Books & Documents. Review.
Cited by
-
DFT investigations and molecular docking as potent inhibitors of SARS-CoV-2 main protease of 4-phenylpyrimidine.J Mol Struct. 2023 Apr 5;1277:134895. doi: 10.1016/j.molstruc.2022.134895. Epub 2022 Dec 30. J Mol Struct. 2023. PMID: 36619799 Free PMC article.
-
Evidences of noncovalent interactions between indole and dichloromethane under different solvent conditions.J Mol Model. 2023 Jul 13;29(8):246. doi: 10.1007/s00894-023-05623-3. J Mol Model. 2023. PMID: 37442832
References
-
- Mesecar A.D. RCSB; 2020. RCSB PDB - 6W63: Structure of COVID-19 Main Protease Bound to Potent Broad-Spectrum Non-covalent Inhibitor X77. - DOI
-
- Kettle J.G., Anjum R., Barry E., Bhavsar D., Brown C., Boyd S., Campbell A., Goldberg K., Grondine M., Guichard S., Hardy C.J., Hunt T., Jones R.D.O., Li X., Moleva O., Ogg D., Overman R.C., Packer M.J., Pearson S., Schimpl M., Shao W., Smith A., Smith J.M., Stead D., Stokes S., Tucker M., Ye Y. Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. J. Med. Chem. 2018;61:8797–8810. doi: 10.1021/acs.jmedchem.8b00938. - DOI - PubMed
-
- Doi T., Kurokawa Y., Sawaki A., Komatsu Y., Ozaka M., Takahashi T., Naito Y., Ohkubo S., Nishida T. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. Eur. J. Cancer. 2019;121:29–39. doi: 10.1016/j.ejca.2019.08.009. - DOI - PubMed
-
- Smith B.D., Kaufman M.D., Lu W.P., Gupta A., Leary C.B., Wise S.C., Rutkoski T.J., Ahn Y.M., Al-Ani G., Bulfer S.L., Caldwell T.M., Chun L., Ensinger C.L., Hood M.M., McKinley A., Patt W.C., Ruiz-Soto R., Su Y., Telikepalli H., Town A., Turner B.A., Vogeti L., Vogeti S., Yates K., Janku F., Razak A.R. Abdul, Rosen O., Heinrich M.C., Flynn D.L. Ripretinib (DCC-2618)is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell. 2019;35:738–751.e9. doi: 10.1016/j.ccell.2019.04.006. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous